The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.
-
Paragraph 0251
(2016/12/26)
ERβ ligands. Part 5: Synthesis and structure-activity relationships of a series of 4′-hydroxyphenyl-aryl-carbaldehyde oxime derivatives
A series of 4′-hydroxyphenyl-aryl-carbaldehyde oximes (5b) was prepared and found to have high affinity (4 nM) and modest selectivity (39-fold) for estrogen receptor-β (ERβ). Substitution of one of the core rings of the scaffold based around these novel ligands further expanded our knowledge in the quest toward achieving high affinity and selectivity for ERβ. An X-ray co-crystal of structure 11 revealed that the oxime moiety was mimicking the C-ring of genistein, as previously predicted by SAR and docking studies.
Mewshaw, Richard E.,Bowen, S. Marc,Harris, Heather A.,Xu, Zhang B.,Manas, Eric S.,Cohn, Stephen T.
p. 902 - 906
(2007/10/03)
ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS
This invention provides estrogen receptor modulators having the structure (I) where R1-R5 are as defined in the specification; or a pharmaceutically acceptable salt thereof.
-
Page 27
(2010/02/09)
More Articles about upstream products of 799766-13-5